Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition

Biomaterials

Volumn 82, Issue , 2016, Pages 48-59

  Zuo, Zu Qi ^a   Chen, Kai Ge ^a   Yu, Xiao Yuan ^a   Zhao, Gui ^a   Shen, Song ^a   Cao, Zhi Ting ^b   Luo, Ying Li ^a   Wang, Yu Cai ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer stem cell; Nanoparticle drug delivery system; SiRNA; TGF signaling pathway inhibition; Tumor penetration

Indexed keywords

CELLS; CYTOLOGY; DISEASES; NANOPARTICLES; SIGNALING; STEM CELLS; TISSUE; TUMORS;

CANCER STEM CELLS; DRUG DELIVERY SYSTEM; SIGNALING PATHWAYS; SIRNA; TUMOR PENETRATION;

CELL SIGNALING;

ANTINEOPLASTIC AGENT; LY 364947; NANOPARTICLE; POLO LIKE KINASE 1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; LY-364947; NANOCAPSULE; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; NANOCAPSULES; NEOPLASTIC STEM CELLS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84957594079     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.12.014     Document Type: Article

References (57)

1. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
2. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
3. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
4. Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J.V., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 2012, 12:767-775.
5. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov. 2014, 13:497-512.
6. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
7. Massard C., Deutsch E., Soria J.C. Tumor stem cell targeted treatment: Elimination or differentiation. Ann. Oncol. 2006, 17:1620-1624.
8. Yu F., Yao H., Zhu P.C., Zhang X.Q., Pan Q.H., Gong C., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
9. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. Plos One 2008, 3:e2428.
10. Li X.X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
11. Du Z.Y., Qin R.Y., Wei C.F., Wang M., Shi C.J., Tian R., et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig. Dis. Sci. 2011, 56:741-750.
12. Easwaran H., Tsai H.C., Baylin S.B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell. 2014, 54:716-727.
13. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
14. Kleppe M., Levine R.L. Tumor heterogeneity confounds and illuminates. Nat. Med. 2014, 20:342-344.
15. Axelson H., Fredlund E., Ovenberger M., Landberg G., Pahlman S. Hypoxia-induced dedifferentiation of tumor cells - A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 2005, 16:554-563.
16. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
17. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13:727-738.
18. Harris A.L. Hypoxia - A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
19. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
20. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2784-2789.
21. Liu S.L., Cong Y., Wang D., Sun Y., Deng L., Liu Y.J., et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014, 2:78-91.
22. Tannock I.F., Primeau A., Grantab R., Lee C. Limited penetration of anticancer drugs to cells in solid tumors: a neglected and modifiable cause of drug resistance. J. Clin. Oncol. 2005, 23:9563s.
23. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
24. Marcucci F., Corti A. Improving drug penetration to curb tumor drug resistance. Drug Discov. Today 2012, 17:1139-1146.
25. Gilleron J., Querbes W., Zeigerer A., Borodovsky A., Marsico G., Schubert U., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 2013, 31:638-646.
26. Cheng C.J., Tietjen G.T., Saucier-Sawyer J.K., Saltzman W.M. A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 2015, 14:239-247.
27. Yu H.Y., Tang Z.H., Zhang D.W., Song W.T., Zhanga Y., Yang Y., et al. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J. Control Release 2015, 205:89-97.
28. Zhu X., Xu Y.J., Solis L.M., Tao W., Wang L.Z., Behrens C., et al. Long-circulating siRNA nanoparticles for validating prohibitin1-targeted non-small cell lung cancer treatment. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:7779-7784.
29. Uster P.S., Working P.K., Vaage J. Pegylated liposomal doxorubicin (DOXIL (R), CAELYX (R)) distribution in tumour models observed with confocal laser scanning microscopy. Int. J. Pharm. 1998, 162:77-86.
30. Chauhan V.P., Stylianopoulos T., Boucher Y., Jain R.K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. 2011, 2:281-298.
31. Erkan M., Hausmann S., Michalski C.W., Fingerle A.A., Dobritz M., Kleeff J., et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepat. 2012, 9:454-467.
32. Zhang L.Z., Nishihara H., Kano M.R. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol. Pharm. Bull. 2012, 35:761-766.
33. Ernsting M.J., Murakami M., Roy A., Li S.D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control Release 2013, 172:782-794.
34. Stapleton S., Milosevic M., Tannock I.F., Allen C., Jaffray D.A. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. J. Control Release 2015, 211:163-170.
35. Yang X.Z., Dou S., Sun T.M., Mao C.Q., Wang H.X., Wang J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J. Control Release 2011, 156:203-211.
36. Hu K.J., Law J.H., Fotovati A., Dunn S.E. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 2012, 14:R22.
37. Tan J., Li Z.M., Lee P.L., Guan P.Y., Aau M.Y., Lee S.T., et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 2013, 3:1156-1171.
38. Dimri M., Cho J.H., Kang M., Dimri G.P. PLK1 inhibition down-regulates polycomb group protein BMI1 via modulation of the miR-200c/141 cluster. J. Biol. Chem. 2015, 290:3033-3044.
39. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3460-3465.
40. Kano M.R., Komuta Y., Iwata C., Oka M., Shirai Y., Morishita Y., et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009, 100:173-180.
41. Meng H., Zhao Y., Dong J.Y., Xue M., Lin Y.S., Ji Z.X., et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 2013, 7:10048-10065.
42. Molina I., Li S.M., Martinez M.B., Vert M. Protein release from physically crosslinked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials 2001, 22:363-369.
43. Wang H.X., Yang X.Z., Sun C.Y., Mao C.Q., Zhu Y.H., Wang J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35:7622-7634.
44. Wang H.X., Xiong M.H., Wang Y.C., Zhu J., Wang J. N-Acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver. J. Control Release 2013, 166:106-114.
45. Sun R., Liu Y., Li S.Y., Shen S., Du X.J., Xu C.F., et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 2015, 37:405-414.
46. Sreerama L., Sladek N.E. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell-line exhibiting oxazaphosphorine-specific acquired-resistance. Cancer Res. 1994, 54:2176-2185.
47. Marcato P., Dean C.A., Liu R.Z., Coy K.M., Bydoun M., Wallace M., et al. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol. Oncol. 2015, 9:17-31.
48. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 2009, 13:2236-2252.
49. Sun T.M., Wang Y.C., Wang F., Du J.Z., Mao C.Q., Sun C.Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
50. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69:1302-1313.
51. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1:555-567.
52. Francescangeli F., Patrizii M., Signore M., Federici G., Di Franco S., Pagliuca A., et al. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells 2012, 30:1819-1830.
53. Joshi K., Banasavadi-Siddegowda Y., Mo X.K., Kim S.H., Mao P., Kig C., et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013, 31:1051-1063.
54. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
55. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
56. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
57. Dou S., Yang X.Z., Xiong M.H., Sun C.Y., Yao Y.D., Zhu Y.H., et al. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2(+) breast cancer. Adv. Healthc. Mater. 2014, 3:1792-1803.